80 Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients — an intermediate analysis after ten years experience

Kovács, G.; Wirth, B.; Bertermann, H.; Galalae, R.; Kohr, P.; Wilhelm, R.; Kimmig, B.

doi:10.1016/s0360-3016(97)85420-x

Cited by 22 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median number of patients accrued per institution was 8 (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20], and the average was 9 patients. The average monthly accrual for the study was 5.9 patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321

Hsu¹,

Bae²,

Shinohara³

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-To estimate the rate of late grade 3 or greater genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) following treatment with external beam radiation therapy and prostate high dose rate (HDR) brachytherapy.Methods and Materials-Each participating institution submitted CT based HDR brachytherapy dosimetry data electronically for credentialing and for each study patient. Patients with locally confined T1c-T3b prostate cancer were eligible for this study. All patients were treated with 45 Gy in 25 fractions from external beam radiotherapy and one HDR implant delivering 19 Gy in 2 fractions. All AEs were graded according to CTCAEv3.0. Late GU/ GI AEs were defined as those occurring more than nine months from the start of the protocol treatment, in patients with at least 18 months of potential follow-up.Results-A total of 129 patients from 14 institutions were enrolled in this study. 125 patients were eligible and AE data was available for 112 patients. The pretreatment characteristics of the patients were as follows: T1c-T2c 91%, T3a-T3b 9%, PSA ≤ 10 70%, PSA >10-≤20 30%, GS 2-6 10%, GS 7 72%, and GS 8-10 18%. At a median follow-up time of 29.6 months, 3 acute and 4 late grade 3 GU/GI AEs were reported. The estimated rate of late grade 3-5 GU and GI AE at 18 months was 2.56%.Conclusion-This is the first prospective, multi-institutional trial of CT based HDR brachytherapy and external beam radiotherapy. The technique and doses used in this study resulted in acceptable levels of adverse events.

show abstract

Section: Resultsmentioning

confidence: 99%

“…(6-10) Kovacs et al reported one of the earliest experiences using HDR brachytherapy boost at University of Kiel. (10)(11)(12) Patients treated were mostly T2b-T3 tumors and high grade tumors. They used a combination of split course external beam radiotherapy and two 15 Gy HDR treatments.…”

Section: Introductionmentioning

confidence: 99%

Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321

Hsu¹,

Bae²,

Shinohara³

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…Kovacs et al [14] reported in a large series of 171 patients an excellent local control rate of 89% for T1/T2 and 85% for T3 Stages using 2 HDR brachytherapy fractions of each 15 Gy combined with 50 Gy of EBRT. Borghede et al [7] and Dinges et al [9] reported promising preliminary results of transperineal HDR brachytherapy combined with EBRT.…”

Section: Discussionmentioning

confidence: 99%

3D Interstitial HDR Brachytherapy Combined with 3D External Beam Radiotherapy and Androgen Deprivation for Prostate Cancer Preliminary Results

Martin¹,

Hey-Koch²,

Strassmann³

et al. 2000

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…The use of high dose rate (HDR) afterloading for prostate implants has also developed, combining the recent developments of transrectal ultrasound 11 and HDR remote afterloading units. Kiel in 1986, 17 Seattle in 1989 18 and Michigan in 1991 19 were some of the early centres to adopt the technique of external beam and a HDR BT boost. Mount Vernon implanted their first patient in 1997.We will describe both methods.…”

Section: Introductionmentioning

confidence: 99%

prostate brachytherapy: a review of current practice

Bownes

Flynn²

2004

J Radiother Pract

View full text Add to dashboard Cite

There is currently great interest in the treatment of prostate cancer due to its increasing profile in the older male population. In recent years brachytherapy has become a viable treatment option. Low dose rate implants using permanently implanted radioactive seeds and high dose rate treatments using afterloading machines are two methods regularly used for the treatment of this disease. Both techniques require close integration between imaging and the placement of the radioactive sources. Future developments in imaging will lead to improved targeting of the radiation to diseased areas of the prostate and interactive treatment planning. This review paper describes the current status of the treatment of prostate cancer by brachytherapy, references current published results and examines radiation protection issues.

show abstract

80 Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients — an intermediate analysis after ten years experience

Cited by 22 publications

References 0 publications

Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321

Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321

3D Interstitial HDR Brachytherapy Combined with 3D External Beam Radiotherapy and Androgen Deprivation for Prostate Cancer Preliminary Results

prostate brachytherapy: a review of current practice

Contact Info

Product

Resources

About